3D Liver Fibrosis Models in Lab: A Novel Modality for Drug Screening
Pharmacology Research & Perspectives · 2026-08 · 14 (4)
DOI: 10.1002/prp2.70306 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 31.07.2026. Verfasst von Hani Keshavarz Alikhani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Academic Center for Educatio…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Models, Biological. Die Arbeit nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Liver fibrosis is the common consequence of liver injury caused by a variety of chronic liver disorders. This condition leads to the development of more severe complications, particularly cirrhosis and hepatocellular carcinoma. Despite abundant studies, the fundamental cell and molecular mechanisms of liver fibrosis are still unknown. There are many key players involved in the initiation and progression of liver fibrosis. Thus, the specific type of underlying disease and the study's objectives should be considered while choosing suitable models for liver fibrosis. Numerous in vitro and in vivo models have been generated to investigate liver fibrosis and proposed for drug screening and toxicology; however, there are no ideal in vitro models for drug discovery yet. In this review, we introduced the available in vitro models and highlighted certain platforms such as organoids and liver‐on‐a‐chip for investigating liver fibrosis. Furthermore, we discussed the current challenges and potential application of each model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Academic Center for Education, Culture and Research, Tehran, Iran.
- Institute for Regenerative Medicine, Sechenov University, Moscow, Russia.
- Molecular Medicine Department, Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran.
- World-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov University, Moscow, Russia.
- Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
- Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Fatemeh Majidi, Elham Rismani, Daria Kuznetsova, Massoud Vosough, Abbas Piryaei
Zitieren
APA
Alikhani, H. K., Majidi, F., Ghasemzad, M., Shpichka, A., Nestorova, A., Hendi, Z., Rismani, E., Kuznetsova, D., Timashev, P., Vosough, M., & Piryaei, A. (2026). 3D Liver Fibrosis Models in Lab: A Novel Modality for Drug Screening. Pharmacology Research & Perspectives, 14(4). https://doi.org/10.1002/prp2.70306
Vancouver
Alikhani HK, Majidi F, Ghasemzad M, Shpichka A, Nestorova A, Hendi Z, et al. 3D Liver Fibrosis Models in Lab: A Novel Modality for Drug Screening. Pharmacology Research & Perspectives. 2026;14(4). doi:10.1002/prp2.70306
BibTeX
@article{Alikhani2026,
author = {Alikhani, Hani Keshavarz and Majidi, Fatemeh and Ghasemzad, Mahsa and Shpichka, Anastasia and Nestorova, Anastasia and Hendi, Zahra and Rismani, Elham and Kuznetsova, Daria and Timashev, Peter and Vosough, Massoud and Piryaei, Abbas},
title = {3D Liver Fibrosis Models in Lab: A Novel Modality for Drug Screening},
journal = {Pharmacology Research & Perspectives},
year = {2026},
volume = {14},
number = {4},
doi = {10.1002/prp2.70306}
}
EUVIMED